[go: up one dir, main page]

NO20020968L - Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater forfremstillingen derav - Google Patents

Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater forfremstillingen derav

Info

Publication number
NO20020968L
NO20020968L NO20020968A NO20020968A NO20020968L NO 20020968 L NO20020968 L NO 20020968L NO 20020968 A NO20020968 A NO 20020968A NO 20020968 A NO20020968 A NO 20020968A NO 20020968 L NO20020968 L NO 20020968L
Authority
NO
Norway
Prior art keywords
group
lower alkyl
intermediates
same
compositions containing
Prior art date
Application number
NO20020968A
Other languages
English (en)
Other versions
NO322703B1 (no
NO20020968D0 (no
Inventor
Hideki Fujikura
Toshihiro Nishimura
Kenji Katsuno
Masahiro Hiratochi
Akira Iyobe
Minoru Fujioka
Masayuki Isaji
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17153879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20020968(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of NO20020968D0 publication Critical patent/NO20020968D0/no
Publication of NO20020968L publication Critical patent/NO20020968L/no
Publication of NO322703B1 publication Critical patent/NO322703B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20020968A 1999-08-31 2002-02-27 Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater for fremstillingen derav NO322703B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24680099 1999-08-31
PCT/JP2000/005678 WO2001016147A1 (en) 1999-08-31 2000-08-24 Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof

Publications (3)

Publication Number Publication Date
NO20020968D0 NO20020968D0 (no) 2002-02-27
NO20020968L true NO20020968L (no) 2002-04-26
NO322703B1 NO322703B1 (no) 2006-11-27

Family

ID=17153879

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020968A NO322703B1 (no) 1999-08-31 2002-02-27 Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater for fremstillingen derav

Country Status (28)

Country Link
US (4) US6972283B2 (no)
EP (1) EP1213296B1 (no)
JP (1) JP3989730B2 (no)
KR (1) KR100591585B1 (no)
CN (1) CN1145635C (no)
AT (1) ATE264337T1 (no)
AU (1) AU782330B2 (no)
BG (1) BG65388B1 (no)
BR (1) BRPI0013667B8 (no)
CA (1) CA2382480C (no)
CZ (1) CZ303372B6 (no)
DE (1) DE60009929T2 (no)
DK (1) DK1213296T3 (no)
ES (1) ES2216937T3 (no)
HU (1) HU229581B1 (no)
IL (2) IL148384A0 (no)
MX (1) MXPA02002271A (no)
NO (1) NO322703B1 (no)
NZ (1) NZ517439A (no)
PL (1) PL203124B1 (no)
PT (1) PT1213296E (no)
RU (1) RU2232767C2 (no)
SK (1) SK286600B6 (no)
TR (1) TR200201082T2 (no)
TW (1) TW579378B (no)
UA (1) UA71994C2 (no)
WO (1) WO2001016147A1 (no)
ZA (1) ZA200201991B (no)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
WO2001068660A1 (en) 2000-03-17 2001-09-20 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
AU2002210990A1 (en) * 2000-11-02 2002-05-15 Ajinomoto Co. Inc. Novel pyrazole derivatives and diabetes remedies containing the same
JP4591781B2 (ja) * 2000-11-02 2010-12-01 味の素株式会社 新規ピラゾール誘導体及びそれらを含有する糖尿病治療薬
CA2429833A1 (en) * 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
WO2002053573A1 (en) 2000-12-28 2002-07-11 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and use thereof in medicines
DE60230591D1 (de) * 2001-02-26 2009-02-12 Kissei Pharmaceutical Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
EP1364958B1 (en) 2001-02-27 2010-09-08 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP4590159B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
ATE442148T1 (de) 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
JP2004536047A (ja) * 2001-04-11 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー 糖尿病処置用ｃ−アリールグルコシドのアミノ酸複合体および方法
EP1389621A4 (en) * 2001-04-27 2005-05-11 Ajinomoto Kk N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
EP1400529A4 (en) * 2001-05-30 2007-12-19 Kissei Pharmaceutical GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
EP1405859A4 (en) * 2001-06-20 2008-01-23 Kissei Pharmaceutical NITROGENIC HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, MEDICAL USE AND INTERMEDIATE PRODUCTS CONTAINING THEREOF
WO2003011880A1 (fr) * 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
WO2003020737A1 (en) * 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
AU2003231517A1 (en) * 2002-04-26 2003-11-10 Ajinomoto Co., Inc. Preventive/remedy for diabetes
US7956041B2 (en) 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
DE10231370B4 (de) * 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE60332743D1 (de) * 2002-08-08 2010-07-08 Kissei Pharmaceutical Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
CN100351263C (zh) * 2002-08-08 2007-11-28 橘生药品工业株式会社 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
US7414072B2 (en) * 2002-08-09 2008-08-19 Taisho Pharmaceutical Co., Ltd. Aryl 5-thio-β-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
CN100413878C (zh) * 2002-08-23 2008-08-27 橘生药品工业株式会社 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
AU2003262262A1 (en) * 2002-08-27 2004-03-19 Kissei Pharmaceutical Co., Ltd. Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
JP4530855B2 (ja) * 2002-10-04 2010-08-25 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JPWO2004050122A1 (ja) * 2002-12-04 2006-03-30 キッセイ薬品工業株式会社 高血糖症に起因する疾患の予防又は治療剤
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
AU2003289440A1 (en) * 2002-12-25 2004-07-22 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
CN1761676A (zh) 2003-04-01 2006-04-19 大正制药株式会社 杂芳基5－硫代－β－D－吡喃葡糖苷衍生物及含有该衍生物的糖尿病治疗药
EP1609799A4 (en) * 2003-04-01 2008-10-29 Taisho Pharmaceutical Co Ltd HETEROARYL-5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND AGENTS AGAINST DIABETES THEREOF
ES2377741T3 (es) * 2003-06-20 2012-03-30 Kissei Pharmaceutical Co., Ltd. Derivados de pirazol, composición farmacológica que los contiene e intermedios de producción de los mismos
EP1660509B1 (de) * 2003-08-26 2009-02-04 Boehringer Ingelheim International GmbH Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
MX2007000811A (es) * 2004-07-21 2007-04-02 Kissei Pharmaceutical Inhibidor de avance de enfermedad atribuida a acumulacion anormal de grasa en el higado.
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
JP5086643B2 (ja) 2004-11-18 2012-11-28 キッセイ薬品工業株式会社 １−置換−３−（β−Ｄ−グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
KR101196454B1 (ko) * 2005-03-17 2012-11-01 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체의 제조방법
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
UY29694A1 (es) * 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
WO2007025880A2 (en) * 2005-08-31 2007-03-08 F. Hoffmann-La Roche Ag Pyrazolone derivatives as 11-beta hsd1 inhibitors
UY30082A1 (es) 2006-01-11 2007-08-31 Boehringer Ingelheim Int Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US20080020987A1 (en) * 2006-07-20 2008-01-24 Waldemar Pfrengle Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes
WO2008070692A2 (en) 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
MX2011002166A (es) * 2008-08-28 2011-04-07 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
EA201100152A1 (ru) * 2008-11-20 2011-12-30 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Лекарственные формы производного пиразолона
JP2012509885A (ja) * 2008-11-21 2012-04-26 グラクソスミスクライン エルエルシー 化学プロセス
CN101445528B (zh) * 2008-12-25 2011-06-15 天津药物研究院 硫代葡萄糖衍生物、其制备方法和用途
EP2395983B1 (en) 2009-02-13 2020-04-08 Boehringer Ingelheim International GmbH Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
KR20110126614A (ko) * 2009-02-13 2011-11-23 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도
SI2486029T1 (sl) 2009-09-30 2015-10-30 Boehringer Ingelheim International Gmbh Postopki za pripravo z glukopiranozilom substituiranih benzil-benzenskih derivatov
EP2483286B1 (en) 2009-09-30 2016-07-13 Boehringer Ingelheim International GmbH Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
BR112012008924A2 (pt) 2009-10-20 2019-09-24 Novartis Ag derivado de glicosídeo e usos do mesmo
EA021983B1 (ru) 2009-11-02 2015-10-30 Пфайзер Инк. Производные диоксабицикло[3.2.1]октан-2,3,4-триола
AR079438A1 (es) 2009-12-09 2012-01-25 Panacea Biotec Ltd Derivados de azucar, composiciones farmaceuticas y sus usos
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013523681A (ja) 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
JP2014510782A (ja) 2011-04-14 2014-05-01 ノバルティス アーゲー グリコシド誘導体およびその使用
MX2013014135A (es) 2011-06-03 2014-01-23 Boehringer Ingelheim Int Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
UA113086C2 (xx) 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
PL2981269T3 (pl) 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN113181161A (zh) 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
AR098670A1 (es) 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
LT3862003T (lt) 2013-12-17 2023-12-27 Boehringer Ingelheim Vetmedica Gmbh Sglt-2 inhibitorius, skirtas naudoti taikant medžagų apykaitos sutrikimo gydymą kačių šeimos gyvūnams
EA032558B1 (ru) 2014-01-23 2019-06-28 Бёрингер Ингельхайм Ветмедика Гмбх Лечение метаболических расстройств у представителей собачьих
MX376911B (es) 2014-04-01 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Inhibidores de sglt2 para usarse en el tratamiento de trastornos metabolicos en animales equinos.
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
EP3197429B1 (en) 2014-09-25 2024-05-22 Boehringer Ingelheim Vetmedica GmbH Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
CN104447905A (zh) * 2015-01-14 2015-03-25 佛山市赛维斯医药科技有限公司 一种含硝基苯和双o-葡萄糖苷衍生物、其制备方法和用途
CN104478956A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 苯基双o-葡萄糖苷衍生物、其制备方法和用途
CN104478967A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含腈基苯噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104447907A (zh) * 2015-01-14 2015-03-25 佛山市赛维斯医药科技有限公司 含硝基联苯双葡萄糖苷结构化合物、其制备方法和用途
CN104478969A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含烷氧苯基噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104478962A (zh) * 2015-01-15 2015-04-01 佛山市赛维斯医药科技有限公司 一类卤代苯基s-葡萄糖苷衍生物、其制备方法和用途
CN104497074A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 一种含丙烯腈基和硝基苯o-葡萄糖苷结构化合物及用途
CN104497072A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 含丙烯腈和卤代苯o-葡萄糖苷结构衍生物、其制备方法和用途
CN104478960A (zh) * 2015-01-15 2015-04-01 佛山市赛维斯医药科技有限公司 一种含丙烯腈基和三氟甲苯基o-葡萄糖苷结构化合物和用途
CN104497073A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 含丙烯腈和烷氧苯基o-葡萄糖苷结构的衍生物和用途
KR20190070956A (ko) 2016-10-19 2019-06-21 베링거 인겔하임 인터내셔날 게엠베하 Ssao/vap-1 억제제 및 sglt2 억제제를 포함하는 복합제제 및 이의 용도
MA46742A (fr) 2016-11-10 2019-09-18 Boehringer Ingelheim Int Composition pharmaceutique, méthodes de traitement et leurs utilisations
WO2019201752A1 (en) 2018-04-17 2019-10-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
PE20211467A1 (es) 2018-10-29 2021-08-05 Boehringer Ingelheim Int Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
JP7441946B2 (ja) 2019-11-28 2024-03-01 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 非ヒト動物の乾乳におけるｓｇｌｔ－２阻害剤の使用
MX2022010090A (es) 2020-02-17 2022-09-02 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos.
CN117715639A (zh) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗非人哺乳动物中的肾脏病的用途
KR20240041966A (ko) 2021-07-28 2024-04-01 베링거잉겔하임베트메디카게엠베하 고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
TW202412756A (zh) 2022-05-25 2024-04-01 德商百靈佳殷格翰維美迪加股份有限公司 包含sglt-2抑制劑之水性醫藥組合物
CN120857933A (zh) 2023-03-06 2025-10-28 勃林格殷格翰动物保健有限公司 用于递送特别包含一或多种sglt-2抑制剂的液体药物组合物的系统
KR20250172894A (ko) 2023-04-24 2025-12-09 뉴암스테르담 파마 비.브이. 비정질 오비세트라피브 및 sglt2 억제제 조합
AU2024277852A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
TW202508593A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274111A (en) * 1992-04-07 1993-12-28 American Home Products Corporation Trifluoromethyl substituted 1H-pyrazoles and derivatives thereof
US5264451A (en) * 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
AU2002210990A1 (en) * 2000-11-02 2002-05-15 Ajinomoto Co. Inc. Novel pyrazole derivatives and diabetes remedies containing the same
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use

Also Published As

Publication number Publication date
AU782330B2 (en) 2005-07-21
KR100591585B1 (ko) 2006-06-20
TR200201082T2 (tr) 2002-07-22
CZ2002665A3 (cs) 2002-06-12
UA71994C2 (en) 2005-01-17
DE60009929T2 (de) 2005-03-31
MXPA02002271A (es) 2002-10-31
NZ517439A (en) 2003-03-28
JP3989730B2 (ja) 2007-10-10
PL203124B1 (pl) 2009-08-31
US7115575B2 (en) 2006-10-03
US20050137143A1 (en) 2005-06-23
SK2872002A3 (en) 2003-01-09
ATE264337T1 (de) 2004-04-15
IL148384A (en) 2009-06-15
NO322703B1 (no) 2006-11-27
CN1377363A (zh) 2002-10-30
PT1213296E (pt) 2004-08-31
SK286600B6 (sk) 2009-02-05
BG106451A (en) 2002-09-30
KR20020033781A (ko) 2002-05-07
US20050261205A1 (en) 2005-11-24
HU229581B1 (en) 2014-02-28
DE60009929D1 (de) 2004-05-19
US20040147729A1 (en) 2004-07-29
EP1213296A1 (en) 2002-06-12
TW579378B (en) 2004-03-11
BRPI0013667B8 (pt) 2021-05-25
PL364800A1 (en) 2004-12-13
HUP0203190A2 (hu) 2003-01-28
ES2216937T3 (es) 2004-11-01
CZ303372B6 (cs) 2012-08-22
NO20020968D0 (no) 2002-02-27
EP1213296A4 (en) 2002-09-04
WO2001016147A1 (en) 2001-03-08
BRPI0013667B1 (pt) 2016-06-14
RU2232767C2 (ru) 2004-07-20
US20050261206A1 (en) 2005-11-24
AU6727500A (en) 2001-03-26
DK1213296T3 (da) 2004-08-16
CN1145635C (zh) 2004-04-14
BG65388B1 (bg) 2008-05-30
CA2382480A1 (en) 2001-03-08
ZA200201991B (en) 2003-05-28
IL148384A0 (en) 2002-09-12
BR0013667A (pt) 2002-06-11
EP1213296B1 (en) 2004-04-14
US7056892B2 (en) 2006-06-06
HK1050369A1 (en) 2003-06-20
CA2382480C (en) 2008-09-30
US6972283B2 (en) 2005-12-06
HUP0203190A3 (en) 2003-04-28

Similar Documents

Publication Publication Date Title
NO20020968D0 (no) Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater forfremstillingen derav
DK1270584T3 (da) Glucopyranosyloxybenzylbenzenderivater, medicinske sammensætninger indeholdende samme og intermediater til fremstilling af derivaterne
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
MY129023A (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
AU4396899A (en) Remedies for diabetes
EP1609798A4 (en) CONDENSED HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, AND MEDICAL USE THEREOF
SI1578741T1 (sl) Aromatske spojine kot protivnetna imunomodulatorna in antiproliferativna sredstva
AU9233101A (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
NO993911D0 (no) Remedier/Forebygningsmidler for åndedrettssykdommer
EP1500656A4 (en) BIGUANIDE DERIVATIVE AND DIABETES TREATMENT AGENT CONTAINING
IL169577A0 (en) Oligosaccharide derivatives and pharmaceutical compostions containing the same
NO20042881L (no) Substituerte cykloheksan-derivater

Legal Events

Date Code Title Description
MK1K Patent expired